Critical appraisal of lurasidone in the management of schizophrenia.

Neuropsychiatr Dis Treat · 2012 · PMC3346058 · PMID 22570547

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

45 The percentage of women was very low in both studies (30% for lurasidone and 29.1% for ziprasidone in the first study; 43 22% and 21% for lurasidone 40 and 120 mg/day, 22% for olanzapine, and 23% for placebo in the second study), 45 which may be significant as gender is a risk factor for QTc prolongation and torsades des pointes.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.